U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07238647) titled 'A Trial of HRS-5817 in Obese Participants' on Nov. 16.
Brief Summary: The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of HRS-5817 in obese participants
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: HRS-5817
Single dose of HRS-5817/placebo given subcutaneously (dose level 1 )
DRUG: HRS-5817
Single dose of HRS-5817/placebo given subcutaneously (dose level 2 )
DRUG: HRS-5817
Single dose of HRS-5817/placebo given subcutaneously (dose level 3 )
DRUG: HRS-5817
Single dose of HRS-5817/placebo given subcutaneously (dose ...